---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-029343"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:05:17.457653+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Insmed Q2 net loss $321.7M ($1.70/sh); ARIKAYCE revenue $107.4M (+19% YoY)

## Summary
- ARIKAYCE global revenue $107.4M, up 19% vs Q2 2024; US revenue $68.7M (+7.7%).
- Net loss $321.7M vs $300.6M a year ago; R&D spend $177.2M, SG&A $154.8M on brensocatib launch prep.
- Cash & securities $1.9B; full-year ARIKAYCE revenue guidance reaffirmed at $405-425M.
- Brensocatib PDUFA date Aug 12, 2025; Phase 3 TPIP in PH-ILD to start H2 2025.
- Completed $823.1M equity offering in June; redeemed $569.5M convertible notes in April/May.

## SEC filing metadata
- accession: 0001140361-25-029343
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/0001140361-25-029343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-029343
- JSON: https://secwatch.observer/filing/0001140361-25-029343.json
- Plain text: https://secwatch.observer/filing/0001140361-25-029343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.